Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (October 2021)
29 slides from Rhythm Biosciences's investor presentation, Oct 25, 2021
Slide 1: Investor Presentation
For personal use only Investor Presentation 25 October 2021 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, rep
Slide 3: Introduction
Introduction For personal use only Rhythm’s initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. 3
Slide 4: Investment Highlights
Investment Highlights For personal use only Disruptive and transformative technology Significantly cheaper and easier to administer Globally addressable market Performance better than market standard Manufacturing & Patents secured Initial revenues targeted for 2022 4
Slide 5: Company Overview
Company Overview For personal use only Capital Structure Share Price Chart ASX Code RHY $7,000,000 $1.80 $6,000,000 $1.60 Share Price (at 22 October 2021) $1.36 $1.40 $5,000,000 $1.20 Shares on Issue 208.8 M $4,000,000 $1.00 Unlisted Options 16.8 M $3,000,000 $0.80 $0.60 Market Capitalisation $275 M
Slide 6: Colorectal Cancer
Colorectal Cancer For personal use only COLORECTAL CANCER RISK FACTORS Globally, Colorectal Cancer is currently the 3rd largest cancer by volume with 1.9 million new cases diagnosed annually and 2nd largest cause of cancer related deaths. GLOBAL BURDEN 1.93 million new cases ~940,000 deaths DIAGNOSI
Slide 7: Bowel Cancer Treatment Costs Are Increasing
Bowel Cancer Treatment Costs Are Increasing For personal use only ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments “ The National Bowel Cancer $130,000 $120,000 Cost drivers: $110,000 Screening Program could $100,0002 • Private hospital Ave
Slide 8: Current FIT Pathway – Cumbersome & Not Well Adopted
Current FIT Pathway – Cumbersome & Not Well Adopted (<50% compliance globally) For personal use only FIT Testing Central FIT Sample Pathology Collection lab Process Diagnostic assessment to GP * ➢ Multi step faecal collection, packaging over at least 2 days then posting sample back to a central labo
Slide 9: ColoSTAT - Patient Friendly, Increased Compliance
ColoSTAT® - Patient Friendly, Increased Compliance For personal use only Early detection is the key to survival and reducing the cost of treatment Simple & Routine Patient Journey With ColoSTAT® Government screen / ColoSTAT® has the potential to: GP referral / patient request ✓Significantly increase
Slide 10: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? For personal use only Unlike the FIT, ColoSTAT® is specific for colorectal cancer – not just blood in faeces. How it works ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate with existing pathology lab infrastructure. Col
Slide 11: ColoSTAT - Detailed Development History
ColoSTAT® - Detailed Development History For personal use only Rhythm lists on ColoSTAT® Study 6 Study 7 the ASX prototype test-kit Analytical Clinical trial ISO completed performance completion certification Reagent Global testing complete Two adjunct Program biomarkers manufacturer completed appoi
Slide 12: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting For personal use only Trial Study Design End Points Prospective, cross-sectional, multi- Primary: PATIENT RECRUITMENT SUCCESSFULLY COMPLETED centre clinical trial. Performance of ColoSTAT® for detection of CRC relative to Two cohorts: colo
Slide 13: ColoSTAT Performance
ColoSTAT® Performance For personal use only “83% of unscreened participants prefer a blood test over a faecal test”1 ColoSTAT Sensitivity Performance Comparison • Highly accurate 85% ColoSTAT is 33% more accurate at detecting colorectal cancer than the current market standard Faecal Immunochemical T
Slide 14: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market For personal use only US$38 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States
Slide 15: Market Likely To Expand Significantly
Market Likely To Expand Significantly For personal use only ✓ USA Preventative Services Task Force recommends Colorectal Cancer Screening to commence at age 45. Five years younger than it previously recommended, adding circa 20 million patients to the screening population in the USA alone. ✓ Reducti
Slide 16: Australia – Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups For personal use only 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11
Slide 17: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value For personal use only Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Re
Slide 18: Market Dynamics
Market Dynamics For personal use only Lifestyle factors increasing risk profiles Low screening participation rates Late-Stage Bowel Cancer Treatment Costs Are Increased in young onset Colorectal Cancer Increasing >$100k US draft legislation to reduce screening age to Screening reduced during COVID-1
Slide 19: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage For personal use only Blood based Epigenomics Novigenix Volition Rx Epi proColon® Colox® Nu.q™ Rhythm ColoSTAT® ~$300 per ~$150 per ~$250 per test test $ TBC test Clinical Genomics Colvera™ ~$400 per test ColoSTAT®’s comparative low cost & simplicity len
Slide 20: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage For personal use only 100% 93% 95% 95% 92% 92% 88% 90% 84% 78% 80% 70% 68% 71% Performance / accuracy 60% of ColoSTAT® versus 50% 40% other more expensive, 30% 20% competitor, blood-based 10% tests 0% Colox Colvera Epi proColon ColoSTAT (Study 6) ColoSTA
Slide 21: Market Entry Strategy
Market Entry Strategy For personal use only Rhythm’s strategy is underpinned by: ✓ Proven technology; ✓ Build global manufacturing capability; ✓ Secure commercialisation pathway/s; and ✓ Establish partner networks. 21
Slide 22: Market Entry: Platform Technology Expansion
Market Entry For personal use only Platform Technology Expansion • Confirm Rhythm’s key lead biomarker has global application and is highly expressed in a range of cancers. Building Scale • Shortlist target cancers to focus on. • Complements Rhythm’s simple, low-cost, mass-market cancer diagnostics
Slide 23: Market Entry: Building Scale
Market Entry For personal use only Platform Technology Expansion • Confirmed test-kit manufacture in house (RHY). • Successful transfer of core technology to Building Scale global manufacturer, Biotem. • Third party manufactured test-kits successfully produced and tested in Study 6 with exceptional
Slide 24: Market Entry: Priority Market Entry
Market Entry For personal use only Platform Technology Expansion • United States / Australia / Europe. • China / Japan / Asia / ROW. • Incorporated a 100% owned USA domiciled Building Scale entity. • Increase business development activity and appropriate partner selection. Priority Market Entry • Ta
Slide 25: Market Entry: Regulatory
Market Entry For personal use only Platform Technology Expansion • Regulatory entry for Europe (CE Mark) and Australia (TGA). • Confirmed approach to submit application for CE Mark in advance of Study 7 completion Building Scale and TGA (Australia) regulatory filing. • CE Mark submission and approva
Slide 26: IP – Patents Filed In All Major Target Markets
IP – Patents Filed In All Major Target Markets For personal use only Granted Pending ➢ Licensed from CSIRO. United States France India Australia Germany ➢ Worldwide exclusive licence. China (x2) Italy ➢ Patent wholly owned by Rhythm Biosciences Ltd*. Japan Luxembourg ➢ Expires 2031. United Kingdom N
Slide 27: Summary
Summary For personal use only ✓ Disruptive and transformative technology. ✓ Significantly cheaper and easier to administer. ✓ Globally addressable market. ✓ Performance better than market standard. ✓ Patents secured. ✓ Manufacturing secured. ✓ Initial revenues targeted for late 2022. ✓ Commenced pla
Slide 28: Future Value Inflection Points – FY'22
Future Value Inflection Points – FY’22 For personal use only ✓ CE Mark submission and approval expected in late 2021#. ✓ Progression of TGA (Australia) regulatory application post clinical trial (Study 7) recruitment#. ✓ Development of platform technology opportunities for other cancers. ✓ Advance U
Slide 29: For personal use only
For personal use only Glenn Gilbert CEO, Rhythm Biosciences [email protected] +61 3 8256 2880 www.rhythmbio.com 29
Rhythm Biosciences — Investor Presentation (October 2021) on 6ix